Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Edward van Vaesel describes Asserta's lead compound as a shelved Merck/MSD asset that came with prior pharma safety and pharmacology data. He says that scrutiny and existing data helped at the start, even though the molecule had never been tested in a leukemia model initially.

Related Insights

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.

Roivant's early success came from identifying and building companies around promising drug assets that were deemed non-strategic by large pharmaceutical firms. This approach capitalized on undervalued IP and focused execution, pre-dating the now-common trend of pharma spin-outs.

Pharma's renewed interest in neuroscience is not for early-stage discovery. They are underwriting late-stage, de-risked assets with human proof-of-concept, understood mechanisms, and biomarker data. This strategy allows them to buy optionality on validated programs while avoiding the high cost of early failures.

Discontinued drugs aren't hard to identify; the real challenge is navigating the out-licensing process inside a large pharma company. Without an internal champion to drive the complex approvals for a non-priority asset, promising drugs can languish on the shelf due to corporate inertia, not a desire to hide them.

BGV's massive success, Assertifarma, originated from a Merck reorganization. The founding team, who were being let go, identified a shelved drug intended for inflammation and repurposed it for leukemia, negotiating the license amidst the corporate shuffle. This highlights the hidden opportunities within large pharma portfolios.

Edward van Vaesel says Merck/MSD was reorganizing and firing local staff, which made it willing to discuss out-licensing a shelved compound. Asserta secured rights to a preclinical asset that the big pharma had overlooked. That access was the starting point for the company and a very useful one.

A drug that is proven safe in humans but fails to show efficacy for its initial target is not a total loss. It's a de-risked asset with a known safety profile, making it a prime, low-risk candidate for repurposing into a new disease area, especially for rare diseases with orphan drug protections.

Lyora Therapeutics' model is built on acquiring promising, pre-clinically validated programs that larger companies shelved due to strategic shifts. This "asset-driven" approach allows a new company to rapidly build a pipeline without the cost and time of early-stage discovery, capitalizing on the sunk R&D costs of former owners.

A key organizational flaw prevents valuable shelved assets from being repurposed. In large pharma, actively managing and out-licensing these candidates is not a defined role. Business development is incentivized to in-license new assets, while R&D leaders focus on the active pipeline. This structural gap leaves valuable drugs in corporate limbo.